6533b872fe1ef96bd12d4458
RESEARCH PRODUCT
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Marcus SchmidtNina Ditschsubject
CDK4/6-InhibitorOncologymedicine.medical_specialtymedicine.drug_classMetastasierungPalbociclibCDK4/6 inhibitorHER2-negativMetastasisMammakarzinom03 medical and health scienceschemistry.chemical_compoundbreast cancer0302 clinical medicineBreast cancerInternal medicineMaternity and MidwiferyReview/ÜbersichtmetastasisEndocrine systemMedicineGebFra ScienceAbemaciclib030219 obstetrics & reproductive medicineAromatase inhibitorFulvestrantbusiness.industryhormonrezeptorpositivObstetrics and Gynecologymedicine.diseasechemistryHormone receptorhormone receptor-positivebusinessHER2-negativemedicine.drugdescription
AbstractThe article gives an overview of current treatment options for metastatic hormone receptor-positive and HER2-negative breast cancer. The focus is on combined therapies, e.g., with CDK4/6 inhibition compared with purely endocrine-based therapies in the pre- and postmenopause, presenting the latest study results. The addition of a CDK4/6 inhibitor to endocrine-based therapy with an aromatase inhibitor or fulvestrant leads to a marked improvement in progression-free survival and is independently beneficial whether palbociclib, ribociclib or abemaciclib is involved. The particular clinical status of inhibition of cyclin-dependent kinases argues for its use in the first-line treatment of women with metastatic, hormone receptor-positive and HER2-negative breast cancer compared with the available purely endocrine-based therapies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-12-01 | Geburtshilfe und Frauenheilkunde |